TCG Crossover Management, LLC 13F holdings
TCG Crossover Management, LLC reported 54 positions with a total reported value of $4.2B as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: ABVX ABIVAX SA AMERICAN DEPOSITARY SHARES (19.2%), TNGX TANGO THERAPEUTICS INC (6.8%), CGON CG ONCOLOGY INC (6.3%), COGT COGENT BIOSCIENCES INC (4.5%), IMVT IMMUNOVANT INC (4.1%). Against 2026-03-31 it opened 12 new positions and exited 7. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when TCG Crossover Management, LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 54 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| ABVX ABIVAX SA AMERICAN DEPOSITARY SHARES | 6,007,834 | $800.6M | 19.2% |
| TNGX TANGO THERAPEUTICS INC | 9,081,201 | $283.9M | 6.8% |
| CGON CG ONCOLOGY INC | 3,670,206 | $260.8M | 6.3% |
| COGT COGENT BIOSCIENCES INC | 4,854,436 | $187.9M | 4.5% |
| IMVT IMMUNOVANT INC | 4,457,988 | $171.8M | 4.1% |
| SYRE SPYRE THERAPEUTICS INC | 1,900,582 | $168.7M | 4.1% |
| DNTH DIANTHUS THERAPEUTICS INC | 1,676,624 | $163.4M | 3.9% |
| MIRM MIRUM PHARMACEUTICALS INC | 1,062,049 | $124.3M | 3.0% |
| ZLAB ZAI LAB LTD-ADR | 6,137,627 | $116.6M | 2.8% |
| AMLX AMYLYX PHARMACEUTICALS INC | 6,243,812 | $112.1M | 2.7% |
| GLUE MONTE ROSA THERAPEUTICS INC | 4,622,151 | $111.9M | 2.7% |
| BCRX BIOCRYST PHARMACEUTICALS INC | 11,020,968 | $110.2M | 2.6% |
| VOR VOR BIOPHARMA INC | 5,673,078 | $104.4M | 2.5% |
| TYRA TYRA BIOSCIENCES INC | 3,248,980 | $103.8M | 2.5% |
| DYN DYNE THERAPEUTICS INC | 4,615,144 | $102.5M | 2.5% |
| IRON DISC MEDICINE INC | 1,341,862 | $98.1M | 2.4% |
| RLAY RELAY THERAPEUTICS INC | 4,273,356 | $80.0M | 1.9% |
| SVRA SAVARA INC | 12,362,205 | $76.2M | 1.8% |
| AURA AURA BIOSCIENCES INC | 9,533,333 | $67.7M | 1.6% |
| RVMD REVOLUTION MEDICINES INC | 340,899 | $63.8M | 1.5% |
| TRAX FIRST TRACKS BIOTHERAPEUTICS | 2,895,304 | $58.3M | 1.4% |
| KOD KODIAK SCIENCES INC | 1,445,538 | $56.3M | 1.4% |
| AVTX AVALO THERAPEUTICS INC | 3,017,120 | $55.8M | 1.3% |
| LBRX LB PHARMACEUTICALS INC | 1,447,310 | $47.0M | 1.1% |
| IPSC CENTURY THERAPEUTICS INC | 17,754,430 | $43.4M | 1.0% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 12 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| ZLAB ZAI LAB LTD-ADR | 6,137,627 | $116.6M | 2.8% |
| AURA AURA BIOSCIENCES INC | 9,533,333 | $67.7M | 1.6% |
| TRAX FIRST TRACKS BIOTHERAPEUTICS | 2,895,304 | $58.3M | 1.4% |
| EDIT EDITAS MEDICINE INC | 11,111,111 | $36.0M | 0.9% |
| PHVS PHARVARIS BV | 1,008,229 | $34.9M | 0.8% |
| IFRX INFLARX N V | 14,500,000 | $32.5M | 0.8% |
| ALT ALTIMMUNE INC | 10,000,000 | $30.4M | 0.7% |
| AKTS AKTIS ONCOLOGY INC | 696,560 | $22.5M | 0.5% |
| FBRX FORTE BIOSCIENCES INC | 920,000 | $19.6M | 0.5% |
| RACC RESEARCH ALLIANCE CORP CL A | 500,000 | $5.3M | 0.1% |
| JATT JATT II ACQUISITION CORP | 200,000 | $2.3M | <0.1% |
| EIKN EIKON THERAPEUTICS INC | 37,902 | $494.6K | <0.1% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 7 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| CENTESSA PHARMACEUTICALS PLC | 4,286,480 | $170.3M | 4.9% |
| FULC FULCRUM THERAPEUTICS INC | 5,250,000 | $40.3M | 1.2% |
| LQDA LIQUIDIA TECHNOLOGIES INC | 403,048 | $15.2M | 0.4% |
| URGN UROGEN PHARMA LTD | 405,365 | $7.3M | 0.2% |
| GPCR STRUCTURE THERAPEUTICS INC | 140,411 | $6.8M | 0.2% |
| UPB UPSTREAM BIO INC | 181,063 | $1.6M | <0.1% |
| VTGN VISTAGEN THERAPEUTICS INC | 2,676,580 | $1.5M | <0.1% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| AVTX AVALO THERAPEUTICS INC | 738,383 | 3,017,120 | +308.6% | $55.8M |
| MNPR MONOPAR THERAPEUTICS INC | 132,103 | 203,327 | +53.9% | $18.8M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| ABVX ABIVAX SA AMERICAN DEPOSITARY SHARES | 6,481,085 | 6,007,834 | -7.3% | $800.6M |
| TNGX TANGO THERAPEUTICS INC | 10,531,071 | 9,081,201 | -13.8% | $283.9M |
| RVMD REVOLUTION MEDICINES INC | 576,473 | 340,899 | -40.9% | $63.8M |
| BHVN BIOHAVEN LTD | 4,631,317 | 1,779,952 | -61.6% | $26.5M |
| ALXO ALX ONCOLOGY HOLDINGS INC | 13,011,849 | 5,655,487 | -56.5% | $11.7M |
| ARVN ARVINAS HOLDING CO LLC | 2,387,461 | 707,098 | -70.4% | $5.9M |
| LBRX LB PHARMACEUTICALS INC | 1,839,489 | 1,447,310 | -21.3% | $47.0M |
| TRDA ENTRADA THERAPEUTICS INC | 2,287,500 | 1,060,230 | -53.7% | $7.8M |
| COGT COGENT BIOSCIENCES INC | 4,946,894 | 4,854,436 | -1.9% | $187.9M |
CIK 1839948 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
